Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

2013980 citationsJournal Articlebronze Open Access

Authors

Sam Schulman · Thrombosis and Atherosclerosis Research Institute

Clive Kearon · Thrombosis and Atherosclerosis Research Institute

Ajay K. Kakkar · University College London

Sebastian Schellong · Krankenhaus Dresden-Friedrichstadt

Henry Eriksson · Sahlgrenska University Hospital

David Baanstra · Boehringer Ingelheim (Netherlands)

Anne Mathilde Kvamme

Abstract

Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Diagnosis and Treatment of Venous Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 368, Issue 8, pp. 709-718

DOI: 10.1056/nejmoa1113697

Field-Weighted Citation Impact: 111.19